Packages (Simulation)
Reagent Preparation
Image (I)
Image (II)
Certificate
ELISA Kit for Anti-Complement C3 Convertase Antibody (Anti-C3 Convertase)
C4b2a; C3bBb, complement C.hivin.4.hivin2
- Product No.AEA758Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample Typeserum, plasma and other biological fluids
- Test MethodIndirect ELISA
- Assay Length2h, 30min
- Detection Range3.12-200ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 1.15ng/mL.
- DownloadInstruction Manual
- UOM 48T96T 96T*5 96T*10 96T*100
- FOB
US$ 630
For more details, please contact local distributors! US$ 900 US$ 4050 US$ 7650 US$ 63000
Specificity
This assay has high sensitivity and excellent specificity for detection of Anti-Complement C3 Convertase Antibody (Anti-C3 Convertase).
No significant cross-reactivity or interference between Anti-Complement C3 Convertase Antibody (Anti-C3 Convertase) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of Anti-Complement C3 Convertase Antibody (Anti-C3 Convertase) and the recovery rates were calculated by comparing the measured value to the expected amount of Anti-Complement C3 Convertase Antibody (Anti-C3 Convertase) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 85-102 | 91 |
EDTA plasma(n=5) | 78-94 | 84 |
heparin plasma(n=5) | 80-95 | 80 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Anti-Complement C3 Convertase Antibody (Anti-C3 Convertase) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Anti-Complement C3 Convertase Antibody (Anti-C3 Convertase) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Anti-Complement C3 Convertase Antibody (Anti-C3 Convertase) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 89-97% | 98-105% | 78-104% | 80-92% |
EDTA plasma(n=5) | 78-97% | 90-101% | 79-97% | 88-95% |
heparin plasma(n=5) | 83-102% | 78-101% | 98-105% | 95-105% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
Standard | 2 | Standard Diluent | 1×20mL |
Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
TMB Substrate | 1×9mL | Stop Solution | 1×6mL |
Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 5 times;
5. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
6. Add 50µL Stop Solution. Read at 450nm immediately.
GIVEAWAYS
INCREMENT SERVICES
Magazine | Citations |
Journal of Vascular Surgery | Circulation levels of acute phase proteins in patients with Takayasu arteritis PubMed: 20100644 |
Journal of Neuroimmunology | Acute and prolonged complement activation in the central nervous system during herpes simplex encephalitis Pubmed:27235358 |
Frontiers in Immunology | Leishmania donovani Inhibitor of Serine Peptidases 2 Mediated Inhibition of Lectin Pathway and Upregulation of C5aR Signaling Promote Parasite Survival … Pubmed:29434593 |